ArticleEuropean thyroid journal2025
Analysis of FNAC indication in thyroid nodules assessed as low risk according to various TIRADSs.
Article in European thyroid journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Value of Multimodal Ultrasound in Differentiating Benign from Malignant Cytologically Indeterminate Thyroid Nodules.Cancers · 2026Article
- Review
- Nomogram integrating BRAF V600E, serum biomarkers, and ultrasound features for malignancy risk stratification in C-TIRADS category 3 and 4 thyroid nodules.Frontiers in medicine · 2026Article
- Application of the Newer 2023 Bethesda System for Reporting Cytopathology of Thyroid Nodules and Estimating their Risk of Malignancy.Journal of cytologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid nodule (TN) is a common entity, and TNs assessed by Thyroid Imaging and Reporting Data Systems (TIRADSs) as low-risk lesions (TIRADS 3) can significantly impact the rate of unnecessary biopsy (UN-FNAC). This study reviewed a consecutive series of patients undergoing surgery to analyze TNs assessed as TIRADS 3. Methods: Thyroid surgeries performed from January 2019 to August 2024 were reviewed. Patients with preoperative thyroid ultrasound were selected, and TNs were classified according to American College of Radiology (ACR), European Thyroid Association (EU), and Korean (K) TIRADS. Cases assessed as TIRADS 3 were finally included. Histology was the reference standard to calculate the rate of UN-FNAC. Results: The study series included 284 TNs assessed as TIRADS 3. The risk of malignancy was 8.7% in ACR-, 10.7% in EU-, and 10.1% in K-TIRADS, higher than expected. The frequency of TNs with indication for biopsy according to K-TIRADS (66.7%) was significantly (P = 0.003) higher than ACR-TIRADS (46.7%), with an intermediate value of EU-TIRADS (56.5%). The percentage of cancers with indication for biopsy according to ACR-, EU-, and K-TIRADS was 25%, 50%, and 50%, respectively. The overall rate of UN-FNAC was 95.3% in ACR-TIRADS, 90.3% in EU-TIRADS, and 92.4% in K-TIRADS. Conclusion: How to save on UN-FNACs in low-risk TNs is challenging. Although ACR-TIRADS can be effective in reducing the total number of biopsies, the rate of UN-FNAC remains significant. Alternative strategies should be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.